Our research with the ADA shows that people with diabetes are much worse off under the COVID-19 pandemic, compared to the nation as a whole.
This article reports results of a survey of patients and health care providers regarding their experiences of and challenges with the use of basal insulin.
New dQ&A data tracks GLP-1 & SGLT2 trends, patient/HCP insights, satisfaction, and market shifts to guide diabetes drug decisions.
